The conundrum of relapse in STAT-C therapy: Does HCV play the red queen or rip van winkle?

Seminars in Liver Disease

Volumn 31, Issue 4, 2011, Pages 410-419

  Ralston, Robert ^a,c   Jacobson, Ira ^b   Scull, Margaret ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c University of Missouri   (United States)

Author keywords

direct acting antivirals; Hepatitis C virus; relapse; resistance

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; BOCEPREVIR; DACLATASVIR; MERICITABINE; MICRORNA; PEGINTERFERON ALPHA; RIBAVIRIN; RNA INDUCED SILENCING COMPLEX; TELAPREVIR; VIRUS RNA;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; ARTICLE; CELL CULTURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENDOPLASMIC RETICULUM; GENETIC VARIABILITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LIVER BIOPSY; LIVER CELL; MOLECULAR BIOLOGY; MOLECULAR CLONING; MONOTHERAPY; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; RNA REPLICATION; RNA STRUCTURE; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRAL CLEARANCE; VIREMIA; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; PROTEASE INHIBITORS; RECURRENCE; VIRAL LOAD; VIRUS REPLICATION;

EID: 84455189490     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1297929     Document Type: Article

References (116)

1. Poordad F, McCone J Jr, Bacon B R. et al, SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011 364 13 1195-1206
2. Bacon B R., Gordon S C., Lawitz E et al, HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011 364 13 1207-1217
3. Jacobson I M., McHutchison J G., Dusheiko G et al, ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011 364 25 2405-2416
4. Zeuzem S, Andreone P, Pol S et al, REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011 364 25 2417-2428
5. Pawlotsky J M., Cocquerel L, Durantel D et al. HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses. Gastroenterology 2010 138 1 6-12, e1e2
6. Lange C M., Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther 2010 32 1 14-28
7. Forestier N, Larrey D, Guyader D et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 2011 54 6 1130-1136
8. Reesink H W., Fanning G C., Farha K A. et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010 138 3 913-921
9. McHutchison J G., Lawitz E J., Shiffman M L. et al, IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 361 6 580-593
10. U.S. Food and Drug Administration. US FDA Antiviral Drugs Advisory Committee Briefing Document: Background Material for Boceprevir. Silver Spring, MD U.S. Food and Drug Administration 2011 31
11. U.S. Food and Drug Administration. US FDA Antiviral Drugs Advisory Committee Briefing Document for NDA 201917 Telaprevir 375 mg Tablets. Silver Spring, MD U.S. Food and Drug Administration 2011 22
12. U.S. Food and Drug Administration. US FDA Antiviral Drugs Advisory Committee Briefing Document: Boceprevir Capsules (NDA 202258) Briefing Document. Whitehouse Station, NJ Merck and Co 2011 90
13. U.S. Food and Drug Administration. US FDA Antiviral Drugs Advisory Committee Briefing Document: Telaprevir 375-mg Film-Coated Tablet for the Treatment of Genotype 1 Chronic Hepatitis C. Cambridge, MA Vertex Pharmaceuticals 2011 147
14. Ludmerer S W., Graham D J., Boots E et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005 49 5 2059-2069 (Pubitemid 40631625)
15. Le Pogam S, Seshaadri A, Kosaka A et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008 61 6 1205-1216 (Pubitemid 351753583)
16. Pockros P, Jensen D, Tsai N et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. Paper presented at: European Association for the Study of the Liver 46th Annual Meeting March 30April 3, 2011 Berlin, Germany
17. van Valen L. A new evolutionary law. Evol Theory 1973 1 1-30
18. Domingo E, Escarmís C, Sevilla N et al. Basic concepts in RNA virus evolution. FASEB J 1996 10 8 859-864 (Pubitemid 26184164)
19. Pham T N., Michalak T I. Occult persistence and lymphotropism of hepatitis C viral infection. World J Gastroenterol 2008 14 18 2789-2793
20. Sumpter R Jr, Loo Y M., Foy E et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005 79 5 2689-2699 (Pubitemid 40270547)
21. Shoukry N H., Cawthon A G., Walker C M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004 58 391-424 (Pubitemid 39551992)
22. Tillmann H L., Thompson A J., Patel K et al, German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010 139 5 1586-1592, 1592, e1
23. Walters K A., Katze M G. Using high-throughput genomics to study hepatitis C: what determines the outcome of infection? Antiviral Res 2009 81 3 198-208
24. Sugano M, Hayashi Y, Yoon S et al. Quantitation of hepatitis C viral RNA in liver and serum samples using competitive polymerase chain reaction. J Clin Pathol 1995 48 9 820-825
25. Neumann A U., Lam N P., Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 282 5386 103-107 (Pubitemid 28471138)
26. Guedj J, Dahari H, Rong L et al. New insights into the mechanism of action of interferon-alpha and BMS-790052: a multi-scale mathematical modeling approach. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related Viruses September 812, 2011 Seattle, WA
27. Gowans EJ. Distribution of markers of hepatitis C virus infection throughout the body. Semin Liver Dis 2001 20 1 85-102
28. Idrees M, Lal A, Malik F A. et al. Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol 2011 11 2 442-445
29. Carreño V, Pardo M, López-Alcorocho J M., Rodríguez-Iñigo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis 2006 194 1 53-60
30. Castillo I, Rodríguez-Iñigo E, López-Alcorocho J M., Pardo M, Bartolomé J, Carreño V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006 43 10 1277-1283 (Pubitemid 44706453)
31. Carreño V. Occult hepatitis C virus infection: a new form of hepatitis C. World J Gastroenterol 2006 12 43 6922-6925 (Pubitemid 44834880)
32. Chang M, Williams O, Mittler J et al. Dynamics of hepatitis C virus replication in human liver. Am J Pathol 2003 163 2 433-444 (Pubitemid 36909407)
33. Egger D, Wölk B, Gosert R et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002 76 12 5974-5984 (Pubitemid 34556292)
34. Moradpour D, Penin F, Rice C M. Replication of hepatitis C virus. Nat Rev Microbiol 2007 5 6 453-463 (Pubitemid 46780082)
35. Gosert R, Egger D, Lohmann V et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003 77 9 5487-5492 (Pubitemid 36460961)
36. Rouillé Y, Helle F, Delgrange D et al. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 2006 80 6 2832-2841 (Pubitemid 43346378)
37. Pfeifer U, Thomssen R, Legler K et al. Experimental non-A, non-B hepatitis: four types of cytoplasmic alteration in hepatocytes of infected chimpanzees. Virchows Arch B Cell Pathol Incl Mol Pathol 1980 33 3 233-243 (Pubitemid 10086023)
38. Schaff Z, Tabor E, Jackson D R., Gerety R J. Ultrastructural alterations in serial liver biopsy specimens from chimpanzees experimentally infected with a human non-A, non-B hepatitis agent. Virchows Arch B Cell Pathol Incl Mol Pathol 1984 45 3 301-312 (Pubitemid 14155041)
39. De Vos R, Verslype C, Depla E et al. Ultrastructural visualization of hepatitis C virus components in human and primate liver biopsies. J Hepatol 2002 37 3 370-379 (Pubitemid 34975685)
40. Kasprzak A, Seidel J, Biczysko W, Wysocki J, Spachacz R, Zabel M. Intracellular localization of NS3 and C proteins in chronic hepatitis C. Liver Int 2005 25 4 896-903 (Pubitemid 41038672)
41. Falcón V, Acosta-Rivero N, Chinea G et al. Ultrastructural evidences of HCV infection in hepatocytes of chronically HCV-infected patients. Biochem Biophys Res Commun 2003 305 4 1085-1090 (Pubitemid 36597875)
42. Asselah T, Bièche I, Mansouri A et al. In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol 2010 221 3 264-274
43. Ferraris P, Blanchard E, Roingeard P. Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes. J Gen Virol 2010 91 Pt 9 2230-2237
44. Reiss S, Rebhan I, Backes P et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011 9 1 32-45
45. Knoops K, Kikkert M, Worm S H. et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol 2008 6 9 e226
46. Uchil P D., Satchidanandam V. Architecture of the flaviviral replication complex. Protease, nuclease, and detergents reveal encasement within double-layered membrane compartments. J Biol Chem 2003 278 27 24388-24398 (Pubitemid 37548590)
47. Mackenzie J M., Jones M K., Young P R. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 1996 220 1 232-240 (Pubitemid 26201681)
48. Westaway E G., Mackenzie J M., Kenney M T., Jones M K., Khromykh A A. Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol 1997 71 9 6650-6661 (Pubitemid 27355323)
49. Quinkert D, Bartenschlager R, Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. J Virol 2005 79 21 13594-13605 (Pubitemid 41508172)
50. Syed G H., Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010 21 1 33-40
51. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari F V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008 82 5 2120-2129 (Pubitemid 351293514)
52. Russell R S., Meunier J C., Takikawa S et al. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A 2008 105 11 4370-4375 (Pubitemid 351754387)
53. Brimacombe C L., Grove J, Meredith L W. et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011 85 1 596-605
54. Valli M B., Serafino A, Crema A et al. Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. J Med Virol 2006 78 2 192-201 (Pubitemid 43132563)
55. Timpe J M., Stamataki Z, Jennings A et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008 47 1 17-24 (Pubitemid 351171037)
56. Witteveldt J, Evans M J., Bitzegeio J et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009 90 Pt 1 48-58
57. Catanese M T., Loureiro J, Jones C T. et al. Viral and cellular determinants of HCV cell-to-cell spread. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related Viruses September 812, 2011 Seattle, WA
58. Sigal A, Kim J T., Balazs A B. et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011 477 7362 95-98
59. Hu Y, Shahidi A, Park S, Guilfoyle D, Hirshfield I. Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction. Am J Clin Pathol 2003 119 1 95-100 (Pubitemid 37047902)
60. Sung V M., Shimodaira S, Doughty A L. et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003 77 3 2134-2146 (Pubitemid 36110026)
61. Steffan A, Marianneau P, Caussin-Schwemling C et al. Ultrastructural observations in hepatitis C virus-infected lymphoid cells. Microbes Infect 2001 3 3 193-202 (Pubitemid 32453147)
62. Pham T N., Michalak T I. Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 2008 14 18 2789-2793
63. Zehender G, Meroni L, De Maddalena C, Varchetta S, Monti G, Galli M. Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. J Infect Dis 1997 176 5 1209-1214 (Pubitemid 27460985)
64. Boisvert J, He X S., Cheung R, Keeffe E B., Wright T, Greenberg H B. Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. J Infect Dis 2001 184 7 827-835 (Pubitemid 32881087)
65. Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 2003 101 1 52-57 (Pubitemid 36025886)
66. Sansonno D, Tucci F A., Lauletta G et al. Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. Clin Exp Immunol 2007 147 2 241-248 (Pubitemid 46096001)
67. Laskus T, Radkowski M, Jablonska J et al. Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood 2004 103 10 3854-3859 (Pubitemid 38596305)
68. Lerat H, Rumin S, Habersetzer F et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 1998 91 10 3841-3849 (Pubitemid 28225753)
69. Di Liberto G, Roque-Afonso A M., Kara R et al. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 2006 131 1 76-84 (Pubitemid 44015750)
70. Pham T N., Mulrooney-Cousins P M., Mercer S E. et al. Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection. J Viral Hepat 2007 14 8 537-548 (Pubitemid 47075430)
71. Radkowski M, Gallegos-Orozco J F., Jablonska J et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005 41 1 106-114 (Pubitemid 40066388)
72. Pham T N., MacParland S A., Mulrooney P M. et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004 78 11 5867-5874 (Pubitemid 38661674)
73. Natarajan V, Kottilil S, Hazen A et al. HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals. J Med Virol 2010 82 12 2032-2037
74. Ramirez S, Perez-Del-Pulgar S, Carrion J A. et al. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant 2009 9 7 1591-1601
75. Maggi F, Fornai C, Vatteroni M L. et al. Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J Gen Virol 1997 78 Pt 7 1521-1525 (Pubitemid 27343088)
76. Revie D, Salahuddin S Z. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J 2011 8 346
77. Martínez J L., Rojo F. Metabolic regulation of antibiotic resistance. FEMS Microbiol Rev 2011 35 5 768-789
78. Klepper A, Eng F, Walewski J et al. Contrary to published models of HCV RNA replication, heat denaturation reveals that much of the HCV in natural infections is in double-stranded form. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related Viruses September 812, 2011 Seattle, WA
79. Jones C T., Murray C L., Eastman D K., Tassello J, Rice C M. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007 81 16 8374-8383 (Pubitemid 47242811)
80. Pedersen I M., Cheng G, Wieland S et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007 449 7164 919-922 (Pubitemid 47598616)
81. Chang J, Guo J T., Jiang D, Guo H, Taylor J M., Block T M. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol 2008 82 16 8215-8223
82. Jopling C L. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans 2008 36 Pt 6 1220-1223
83. Randall G, Panis M, Cooper J D. et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 2007 104 31 12884-12889 (Pubitemid 47255249)
84. Henke J I., Goergen D, Zheng J et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008 27 24 3300-3310
85. Jangra R K., Yi M, Lemon S M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010 84 13 6615-6625
86. Roberts A P., Lewis A P., Jopling C L. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res 2011 39 17 7716-7729
87. Sagan S, Sarnow P. Stabilization of the HCV RNA genome by miR-122. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related Viruses September 812, 2011 Seattle, WA
88. Shimakami T, Yamane D, Jangra R K. et al. miR-122 stabilizes hepatitis C virus RNA by an Ago2-dependent mechanism. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related Viruses September 812, 2011 Seattle, WA
89. Negro F. Mechanisms of hepatitis C virus-related insulin resistance. Clin Res Hepatol Gastroenterol 2011 35 5 358-363
90. Rasmussen A L., Diamond D L., McDermott J E. et al. Systems virology identifies a mitochondrial Fatty Acid oxidation enzyme, dodecenoyl coenzyme a delta isomerase, required for hepatitis C virus replication and likely pathogenesis. J Virol 2011 85 22 11646-11654
91. Diamond D L., Syder A J., Jacobs J M. et al. Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog 2010 6 1 e1000719
92. Berger K L., Randall G. Potential roles for cellular cofactors in hepatitis C virus replication complex formation. Commun Integr Biol 2009 2 6 471-473
93. Estrabaud E, De Muynck S, Asselah T. Activation of unfolded protein response and autophagy during HCV infection modulates innate immune response. J Hepatol 2011 55 5 1150-1153
94. Ke P Y., Chen S S. Autophagy: a novel guardian of HCV against innate immune response. Autophagy 2011 7 5 533-535
95. Ke P Y., Chen S S. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest 2011 121 1 37-56
96. Zeuzem S, Poordad F, Gordon S C. et al. Boceprevir resistance-associated variants (RAVs) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin. Paper presented at: European Association for the Study of the Liver 46th Annual Meeting March 30April 3, 2011 Berlin, Germany
97. Jiang M, Vijgen L, Sullivan J et al. Phenotypic characterization of HCV NS3 protease from patient isolates in phase 2 clinical trials of telaprevir. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related Viruses September 812, 2011 Seattle, WA
98. Shimakami T, Welsch C, Yamane D et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 2011 140 2 667-675
99. Kieffer T L., Sarrazin C, Miller J S. et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007 46 3 631-639 (Pubitemid 47436107)
100. Le Pogam S, Seshaadri A, Ewing A et al. RG7128 alone or in combination with pegylated interferon-2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010 202 10 1510-1519
101. Lawitz E, Nguyen T, Younes Z et al. Valopicitabine NM283 plus PEGinterferon in treatment-naive hepatitis C patients with HCV genotype 1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatology 2007 44 223A
102. Ali S, Leveque V, Le Pogam S et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 2008 52 12 4356-4369
103. Fridell R A., Qiu D, Valera L, Wang C, Rose R E., Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011 85 14 7312-7320
104. Lok A, Gardiner D, Lawitz E et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders (Abstract 1356). J Hepatol 2011 54 S536
105. Fried M W., Hadziyannis S J., Shiffman M L., Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011 55 1 69-75
106. Guedj J, Bazzoli C, Neumann A U., Mentré F. Design evaluation and optimization for models of hepatitis C viral dynamics. Stat Med 2011 30 10 1045-1056
107. Guedj J, Dahari H, Shudo E, Smith S, Perelson A. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor RG7128. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related Viruses September 812, 2011 Seattle, WA
108. Pearson J E., Krapivsky P, Perelson A S. Stochastic theory of early viral infection: continuous versus burst production of virions. PLOS Comput Biol 2011 7 2 e1001058
109. Zeuzem S, Schmidt J M., Lee J H., von Wagner M, Teuber G, Roth W K. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998 28 1 245-252 (Pubitemid 28300008)
110. Zeuzem S, Lee J H., Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998 27 4 1149-1156 (Pubitemid 28160503)
111. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996 25 5 591-598 (Pubitemid 26373872)
112. Pawlotsky J M., Dahari H, Neumann A U. et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004 126 3 703-714 (Pubitemid 38298318)
113. Fried M W., Shiffman M L., Reddy K R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 13 975-982
114. Manns M P., McHutchison J G., Gordon S C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 9286 958-965 (Pubitemid 32913521)
115. Hézode C, Forestier N, Dusheiko G et al, PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 360 18 1839-1850
116. McHutchison J G., Everson G T., Gordon S C. et al, PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009 360 18 1827-1838